BeOne Medicines Q3 2026 Earnings: Net Income Soars 208% on 34% Revenue Jump

Bulletin Express11-05

BeOne Medicines Ltd. (BeOne) reported strong third-quarter 2026 results, driven by sustained momentum for BTK inhibitor BRUKINSA and PD-1 antibody TEVIMBRA.

Revenue Surge Total revenue climbed 33.8% year-on-year (YoY) to USD 1.89 billion, with net product revenue up 33.0% to USD 1.86 billion. BRUKINSA contributed USD 1.39 billion, a 33.7% YoY increase, while TEVIMBRA added USD 243.28 million, up 27.6%. China-licensed Amgen products (XGEVA®, BLINCYTO®, KYPROLIS®) generated USD 158.25 million.

Profitability Rebound Gross profit rose 37.6% to USD 1.67 billion, lifting gross margin on product sales to 88.3% (Q3 2025: 85.9%). Operating income advanced to USD 418.68 million from USD 163.11 million. Net income reached USD 384.71 million, a 208.2% YoY jump, translating into diluted EPS of USD 0.25 and diluted earnings of USD 3.28 per ADS.

Spending & Cash Flow • R&D expense grew 26.2% to USD 660.78 million, reflecting pipeline expansion and higher internal development costs. • SG&A expense increased 12.2% to USD 593.46 million, as BeOne continued scaling its U.S. and European commercial organizations. • Free cash flow for the quarter totaled USD 473.53 million (Q3 2025: USD 354.47 million).

Nine-Month Highlights For the first nine months of 2026, revenue climbed 32.9% to USD 5.11 billion and net income surged to USD 849.07 million from USD 220.43 million. Free cash flow reached USD 1.07 billion.

Balance Sheet Cash, cash equivalents and restricted cash stood at USD 5.87 billion on 30 September 2026, up from USD 4.61 billion at year-end 2025. Total debt was USD 1.07 billion. The company finished funding its USD 1.25 billion co-development obligation with Amgen during the quarter.

Updated Guidance & Strategy Management reiterated its focus on global commercial expansion of BRUKINSA and TEVIMBRA, advancing a diversified oncology pipeline, and leveraging recently opened manufacturing facilities in New Jersey and Suzhou.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment